Dr. Reddy’s drug prices in crosshairs of two states

Eric Palmer Generic Dr. Reddy's Laboratories, which already has had to defend its drug pricing to a couple of members of Congress, is now being called to account by the attorneys ...

Introducing FierceBiotech’s new podcast

Damian Garde Welcome to FierceBiotech Radio, a podcast in which we'll chat with industry experts, newsmakers and veterans on issues affecting the business of biopharma. The idea ...

Eisai wins an early FDA nod for its self-described cancer blockbuster

Damian Garde Eisai is counting on its new cancer drug to eventually bring in more than $ 1 billion a year, and now, thanks to an early FDA approval, the Japanese drugmaker has a head ...

Pakistan struggles to fill top spot at drug regulator as woes mount for industry

EJ Lane SINGAPORE–Sometimes it must seem to Pakistan's health authorities they can do nothing right in regulating the nation's pharmaceutical industry. FiercePharma News

Fujifilm’s Toyama unit set to publish promising early clinical results in treating Ebola

EJ Lane SINGAPORE–Fujifilm's Toyama Chemical is readying a study for a scientific journal stating that its Avigan (favipiravir) influenza drug has shown promise in treating ...

U.S. Chamber knocks IP laggards India, Indonesia, Thailand and Vietnam in Asia

EJ Lane SINGAPORE–India, Indonesia, Thailand and Vietnam are at the bottom in terms of protections for intellectual property, and much of the rest of Asia is ranked near them ...

India’s Cipla presses court to not honor Novartis Onbrez patent citing Lupin license deal

EJ Lane India's Cipla argued before the Delhi High Court against the Novartis patent for its Onbrez (indacaterol) COPD drug, saying the patent need not be honored because the Swiss ...

Activists come for the foundering Aegerion as Denner takes a stake

Damian Garde A syndicate led by activist investor Alex Denner has acquired roughly 5.8% of Aegerion Pharmaceuticals, contending that the struggling biotech's shares are undervalued ...

Astellas bets on Immunomic’s allergy vaccine in a $75M deal

Damian Garde Astellas Pharma is teaming up with biotech Immunomic Therapeutics on a vaccine that could relieve a common allergy that affects millions in its native Japan. FierceBiotech ...

Hedge fund exec aims new legal weapon at Big Pharma’s ‘evergreened’ patents

Emily Wasserman As companies, regulators and advocacy groups lobby to bring certain branded products off-patent, a new voice is joining the chorus. U.S. hedge fund manager Kyle Bass, ...

Abbott, unfazed by political tensions, closes deal for Russia’s Veropharm

Carly Helfand Mounting political tensions between Russia and the West may have recently scared Germany's Fresenius out of a partnership in the country. But they won't spook ...

FDA slaps down Bristol-Myers’ marketing pitch for hep C drug daclatasvir

John Carroll The FDA has slapped down Bristol-Myers Squibb's closely watched hep C drug daclatasvir, handing out a complete response letter for the linchpin drug in its cocktail ...
Page 5 of 34« First...34567...102030...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS